title: Mucosal and systemic fungal infections in patients with AIDS: prophylaxis and treatment.
abstract: In countries where highly active antiretroviral therapy (HAART) is widely available, a decrease in the incidence of fungal infections has been observed in the last 5 years compared with countries that cannot afford this treatment. Even refractory fungal infections may be controlled when HAART is given to patients, and end-stage AIDS infections, such as aspergillosis, are now only infrequently seen. In contrast, fungal infections in certain regions, such as penicilliosis in Southeast Asia or cryptococcosis in Sub-Saharan Africa, are a growing problem. Antifungal therapy for documented infections has not changed very much during recent years; however, new drugs such as caspofungin and voriconazole may be more effective in the treatment of opportunistic fungal infections, in particular, those involving resistant organisms. Secondary antifungal prophylaxis for many opportunistic pathogens can now be temporarily or even permanently discontinued in many HIV-positive patients who have a marked improvement in immune function parameters, such as CD4(+) cell counts, after initiation of HAART. The link between effective virustatic control of HIV infection and a decreasing incidence of fungal infections has been recognised; and so, despite the availability of very effective new antifungal drugs, the cornerstone of treatment and prevention of opportunistic fungal infections in patients with HIV infection is effective antiretroviral therapy including protease inhibitors.
authors.affiliation: Department of Internal Medicine, Charité Campus Mitte, Berlin, Germany. markus.ruhnke@charite.de
authors.forename: Markus
authors.initials: M
authors.lastname: Ruhnke
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000097:blood / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000097:blood / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D001228:Aspergillosis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D002177:Candidiasis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D003047:Coccidioidomycosis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D003453:Cryptococcosis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D004347:Drug Interactions; D005260:Female; D006660:Histoplasmosis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D009181:Mycoses / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control
chemical_list: D019380:Anti-HIV Agents; D000935:Antifungal Agents